Compare · AIMT vs AZRX
AIMT vs AZRX
Side-by-side comparison of Aimmune Therapeutics, Inc. (AIMT) and AzurRx BioPharma, Inc. (AZRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMT and AZRX operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- AZRX has more recent analyst coverage (1 ratings vs 0 for AIMT).
- Company
- Aimmune Therapeutics, Inc.
- AzurRx BioPharma, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 1
AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.
Latest AIMT
- SEC Form SC 13G/A filed
- Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
- Nestlé completes acquisition of Aimmune Therapeutics
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation
- ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Latest AZRX
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Other Events
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
- SEC Form 4 filed by Coelho Mary Theresa
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma Announces Reverse Stock Split